Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
47 hedge funds and large institutions have $33.3M invested in Turnstone Biologics in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
18% more funds holding
Funds holding: 40 → 47 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $35M → $33.3M (-$1.7M)
2.88% less ownership
Funds ownership: 57.79% → 54.92% (-2.9%)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$598K |
| 2 |
Millennium Management
New York
|
+$360K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$272K |
| 4 |
Goldman Sachs
New York
|
+$209K |
| 5 |
ZP
Zimmer Partners
New York
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.78M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.26M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$475K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$187K |
| 5 |
State Street
Boston,
Massachusetts
|
-$101K |
TSBX Hedge Fund Activity: Q2 2024 in Review
47 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q2 2024, worth a combined $33.3M — down 4.9% from $35M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TSBX positions and 9 closed out — a net gain of 7 holders — while 11 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $598K. The largest seller was BlackRock, cutting an estimated $1.78M.
- 47 institutional investors held Turnstone Biologics (TSBX) as of Q2 2024, up from 40 in Q1 2024.
- Funds reported $33.3M of Turnstone Biologics stock for Q2 2024, down 4.9% quarter-over-quarter.
- 16 funds opened new Turnstone Biologics positions in Q2 2024 and 9 closed out, a net change of +7 holders.
- The largest Turnstone Biologics buyer in Q2 2024 was Vanguard Group, an estimated $598K added.
- The largest Turnstone Biologics seller in Q2 2024 was BlackRock, an estimated $1.78M sold.
Based on aggregated 13F filings for Q2 2024.